Germany’s Merck KGaA has agreed to buy SpringWorks Therapeutics, adding the US biotech’s portfolio of cancer and rare disease ...

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

Reacting to press speculation, Merck KGaA has acknowledged that talks to buy US biotech SpringWorks are now in the late stages and are revolving around an offer of around $47 per share.

Merck KGaA to buy Springworks for $3.9 billion Merck KGaA (OTCPK:MKGAF) is set to acquire SpringWorks Therapeutics (SWTX) for ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...

raises its EV prices in Canada and Merck KGaA (MRK) seeks to acquire SpringWorks Therapeutics (SWTX) in a $3.9 billion deal. Catalysts host Madison Mills and Ritholtz Wealth Management chief ...

Meanwhile, major mergers are shaping the biotech landscape. Germany's Merck KGaA has moved to acquire SpringWorks Therapeutics, anticipating a future free of certain expiring patents. This purchase ...